The full guidelines are shown here in html or PDF. Notice the curious disclaimer in the footnotes. Also note the acknowledgements, financial support and conflicts of interest on page 291 of the full text document.
Financial support. IDSA.
Potential conﬂicts of interest. H.F.C. has received honoraria and research grants and has served as a consultant to Cubist, Ortho-McNeil,Pﬁzer, Theravance, and Targanta. S. E. C. has received honoraria from Forest and RibX, has served as a consultant for Merck and has received research support from Astellas, Cubist and AdvanDx. R.D. has received research funding from Pﬁzer, Clorox, Sanoﬁ Pasteur, Sage, and GeneOhm. S.L.K. has received grant funding from Pﬁzer, has served as MRSA Leadership Advisor to Pﬁzer, and is participating in a pediatric daptomycin study. A.W.K. has received honoraria and grants from Cubist Pharmaceuticals, Merck, Wyeth, and Pﬁzer and has served as a consultant for Cubist Pharmaceuticals, Theravance, Astellas, Pﬁzer, Merck, and OrthoMcNeil and has owned stock from Cubist Pharmaceutical, Pﬁzer, and Johnson and Johnson. D.P.L. has received research support from Cubist, Johnson & Johnson, and Theravance and has served as a speaker for Cubist. B.E.M. has served as a consultant and received research support from Johnson & Johnson, Astellas, Pﬁzer, Cubist, Theravance, Targanta, Sanoﬁ- Aventis, Vicuron Pharmaceuticals, and Wyeth-Ayerst. M.R. has received grants and or has served as a consultant speaker for the Pﬁzer, Cubist, Theravance/Astellas, Targanta, and Johnson & Johnson. D.A.T. has served on the advisory board to Pﬁzer, Ortho-McNeil, Astellas, Schering-Plough, and Replidyne. All other authors: no conﬂicts.
Evidence-based guidelines for the management of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections were prepared by an Expert Panel of the Infectious Diseases Society of America (IDSA). The guidelines are intended for use by health care providers who care for adult and pediatric patients with MRSA infections. The guidelines discuss the management of a variety of clinical syndromes associated with MRSA disease, including skin and soft tissue infections (SSTI), bacteremia and endocarditis, pneumonia, bone and joint infections, and central nervous system (CNS) infections. Recommendations are provided regarding vancomycin dosing and monitoring, management of infections due to MRSA strains with reduced susceptibility to vancomycin, and vancomycin treatment failures.
It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. The IDSA considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient’s individual circumstances.
Received October 28, 2010.
Accepted November 17, 2010.